Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment.
Major depressive disorder (MDD) often occurs during pegylated IFN-alpha2 (IFN-alpha) treatment. Identifying who is at risk for MDD in this population is essential, and epidemiological studies suggest that sleep may be related to depression risk. Controlling for pre-existing depression symptoms, we therefore examined whether sleep quality prior to IFN-alpha treatment would predict subsequent MDD incidence during IFN-alpha treatment. Adults with hepatitis C but without current clinical MDD (n=86) were evaluated prior to IFN-alpha treatment and then prospectively monitored during treatment using self-report measures of sleep quality (PSQI), depression (BDI), and anger and irritability (AIAQ), as well as with Structured Clinical Interviews for DSM-IV Axis I Disorders (SCID-I). During IFN-alpha treatment, 19% developed MDD, 19% developed subsyndromal depression with irritability, and one developed mania. Controlling for baseline depression symptoms and past history of depression, patients with worse sleep quality (PSQI > or = 10) prior to treatment had a significantly shorter time until they developed MDD or any severe psychiatric problem. These findings may have important implications for understanding, predicting, and possibly preventing depression, particularly in individuals treated with IFN-alpha.
Franzen
Peter L
PL
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. franzenpl@upmc.edu
Buysse
Daniel J
DJ
Rabinovitz
Mordechai
M
Pollock
Bruce G
BG
Lotrich
Francis E
FE
D000328:Adult; D000704:Analysis of Variance; D003865:Major Depressive Disorder / Q000145:classification / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006306:Health Surveys; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D016898:Interferon-alpha / Q000009:adverse effects*; D007508:Irritable Mood / Q000502:physiology*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012893:Sleep Wake Disorders / Q000139:chemically induced*; D013997:Time Factors
D007155:Immunologic Factors; D016898:Interferon-alpha
Am J Psychiatry. 1995 Jul;152(7):967-72
7793466
Psychiatry Res. 1989 May;28(2):193-213
2748771
N Engl J Med. 2001 Mar 29;344(13):961-6
11274622
Sleep Med Rev. 2000 Jun;4(3):253-262
12531168
J Clin Psychiatry. 2005 Jan;66(1):41-8
15669887
Acta Neurol Scand. 2004 Jul;110(1):6-13
15180801
Am J Psychiatry. 2008 Dec;165(12):1543-50
18765482
J Affect Disord. 2007 Nov;103(1-3):83-90
17292481
Brain Behav Immun. 2004 May;18(3):205-13
15050647
J Affect Disord. 2003 Sep;76(1-3):255-9
12943956
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
Am J Epidemiol. 1997 Jul 15;146(2):105-14
9230772
Brain Behav Immun. 2003 Feb;17 Suppl 1:S119-24
12615197
J Clin Psychiatry. 1992 Jun;53 Suppl:37-41
1613018
N Engl J Med. 1999 Apr 29;340(17):1370
10223879
J Psychosom Res. 2007 Aug;63(2):131-5
17662748
Mol Psychiatry. 2002;7(9):942-7
12399946
Psychosomatics. 2003 Mar-Apr;44(2):104-12
12618532
Biol Psychiatry. 1996 Mar 15;39(6):411-8
8679786
Br J Psychiatry. 1989 Feb;154:201-6
2775946
World J Gastroenterol. 2005 Mar 28;11(12):1769-74
15793861
Neuropsychopharmacology. 2001 Nov;25(5 Suppl):S45-9
11682273
J Neuropsychiatry Clin Neurosci. 1991 Spring;3(2):S44-51
1821222
J Clin Psychiatry. 2003 Jun;64(6):708-14
12823087
J Psychiatr Res. 1997 May-Jun;31(3):377-81
9306295
Psychiatry Res. 1992 Mar;41(3):237-48
1594710
AIDS. 2005 Oct;19 Suppl 3:S174-8
16251815
Psychosomatics. 2004 Mar-Apr;45(2):176
15016930
CNS Drugs. 2005;19(2):105-23
15697325
Aliment Pharmacol Ther. 2006 Oct 15;24(8):1223-30
17014581
J Clin Psychiatry. 2005 Aug;66(8):1050-7
16086622
Behav Sleep Med. 2006;4(2):104-13
16579719
Biol Psychiatry. 2006 Jun 1;59(11):1052-60
16581036
Prog Neuropsychopharmacol Biol Psychiatry. 2002 May;26(4):731-46
12188106
Am J Psychiatry. 2004 Jan;161(1):19-24
14702243
Sleep. 2008 Apr;31(4):473-80
18457234
N Engl J Med. 1998 Nov 19;339(21):1485-92
9819446
JAMA. 1989 Sep 15;262(11):1479-84
2769898
Lancet. 2001 Sep 22;358(9286):958-65
11583749
Endocrinol Metab Clin North Am. 2002 Mar;31(1):15-36
12055986
J Clin Endocrinol Metab. 2004 May;89(5):2119-26
15126529
Sleep. 1996 May;19(4):318-26
8776790
J Psychosom Res. 2002 Sep;53(3):737-40
12217446
Arthritis Rheum. 2005 Apr 15;53(2):272-8
15818653
J Clin Gastroenterol. 2006 Apr;40(4):322-35
16633105
Biol Psychiatry. 2009 Feb 15;65(4):344-8
18801474
J Affect Disord. 2004 Oct 15;82(2):175-90
15488246
Sleep Med. 2007 Apr;8(3):198-208
17368098
J Clin Oncol. 2000 Jun;18(11):2316-26
10829053
Dialogues Clin Neurosci. 2008;10(4):473-81
19170404
Int J Neurosci. 2004 Feb;114(2):245-56
14702212
Ann Clin Psychiatry. 2006 Jan-Mar;18(1):49-56
16517453
Eur J Gastroenterol Hepatol. 2000 May;12(5):505-9
10833092
Brain Behav Immun. 2001 Sep;15(3):199-226
11566046